Dermatology

There is a high risk for contact dermatitis in retail products for skincare, due to the prevalence of allergens.

Research shown at EADV 2022 demonstrated the efficacy of an antibody designed to protect against inflammatory skin disorders.

Research from a double-blind trial suggests a lack of need for clinicians to implement glutamine therapy for burn victims.

The novel OX40 inhibitor molecule showed significant benefit for patients in new EADV 2022 data. A lead author discusses its potential.

The daily TYK2 inhibitor agent was associated with improved rates of psoriasis surface improvement versus apremilast in clinical trials.

New research presented at EADV 2022 suggests positive results for a new JAK1-selective inhibitor for hidradenitis suppurativa.

The Icahn investigator discusses her team's new EADV 2022 data on the JAK inhibitor.

A pair of phase 3 clinical trials presented at EADV 2022 indicate dupilumab significantly improves PN symptoms over 24 weeks.

DaxibotulinumtoxinA-lanm (Daxxify) is the first and only neuromodulator stabilized with Peptide Exchange Technology (PXT) and addresses the treatment duration effect.

Large numbers of vitiligo patients around the world have reported differing outcomes, with darker skin types expressing the more significant severity, according to new findings.

Research presented at EADV 2022 sees positive outcomes with the targeted therapy for patients of varied backgrounds with vitiligo.

Recent research from the National Psoriasis Foundation (NPF) found that 1 in 3 individuals living with psoriatic conditions experience depression.

The latest indications for the novel selective antibody will make it available as a treatment for pustular psoriasis.

A study from Germany elucidated new information on the rare uncombable hair syndrome, changing the ways in which the syndrome may be analyzed.

Nonsegmental vitiligo not only affects the skin but can destroy melanocytes in other areas of the body including the eye, new research shows.

A recent study in Finland finds 2 major contributing factors to allergic disease in infants with familial risk.

A recent study indicated no evident VTE risk in patients with eczema, despite FDA black box warnings for the drug class.

Investigators found that body surface area involvement on admission, malignant neoplasm, and connective tissue disease were independent factors associated with leukopenia in SJS/TEN.

Dermatologists addressed the overprescribing of antibiotics while acknowledging the necessity of antibiotics. Excessive prescribing practices contribute to the emergence of antibiotic resistance and furthers a patient's risk for resistant infections and treatment failures.

Biologic agents may reduce the risk of mental health disorders among patients with moderate-to-severe psoriasis who discontinued treatment with conventional systemic agents, researchers in Canada found.

Among flares identified in outpatient (53%), inpatient (36%), and emergency department (9%) settings, the most utilized treatments were topical corticosteroids (35%), opioids (21%), and other oral treatments.

Investigators identified a correlation between severity of kidney-urinary tract complications and the affected protein involved with intermediate junctional epidermolysis bullosa (JEB).

Despite their tendency to present with more severe psoriasis compared with other races and ethnicities, Asian patients receive significantly less time with a dermatologist.

Both treatments showed tolerable safety as in the phase 2 and 3 trials, but when evaluated in four body regions on patients, upadacitinib surpassed dupilumab in all of them.

Although sharing a common feature of male predominance, alopecia did not seem to occur more frequently in AS patients.